Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancer

Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, shares results from a subgroup analysis of a Phase II study mirroring the patient population of an upcoming study. In this trial, relacorilant and nab-paclitaxel was evaluated in patients with recurrent, platinum-resistant ovarian cancer and it was demonstrated that glucocorticoid receptor modulation with relacorilant can improve the efficacy of nab-paclitaxel. In addition, intermittent relacorilant plus nab-paclitaxel improved progression-free survival, overall survival, and duration of response in the “Phase III population” subgroup, confirming the potential of this combination which will be evaluated in the upcoming Phase III ROSELLA trial (NCT05257408). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.